Source: Annual Congress 2007 - Granulomatous lung diseases including sarcoidosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Refitskaya (Saint-Petersburg, Russian Federation). The use of symbicort in the treatment of patients with I and II stages of pulmonary sarcoidosis. Eur Respir J 2007; 30: Suppl. 51, 643

Member's Comments

No comment yet.

Related content which might interest you: The use fluimucil (N-acetylcysteine) in the treatment in patients with III and IY stages of pulmonary sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 713s Year: 2004 The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 434s Year: 2002 The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Respiratory function in stage II pulmonary sarcoidosis patients Source: Eur Respir J 2001; 18: Suppl. 33, 385s Year: 2001 The radiographic stage and pulmonary function of patients with sarcoidosis Source: Annual Congress 2007 - Granulomatous lung diseases including sarcoidosis Year: 2007 Isophonum usage in treatment of patients with pulmonary tuberculosis and accompanying pathology and elderly patients Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002 Evaluating the effects of pulmonary rehabilitation in patients with COPD in early and late disease stages. Source: Annual Congress 2008 - Impact of rehabilitation programmes in COPD and non-COPD patients Year: 2008 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 The role of determining the levels of collagen type IV in the management of patients with severe chronic obstructive pulmonary disease – Focus on roflumilast Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 Contemporary surgical issues in NSCLC treatment Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer Year: 2007 The pharmacotherapy options for the intensive treatment phase in patients with primarily diagnosed pulmonary tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Efficacy of different preoperational treatment in patients with destructive pulmonary TB Source: Eur Respir J 2005; 26: Suppl. 49, 688s Year: 2005 Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1800663; 10.1183/13993003.00663-2018 Year: 2019 Long-term treatment with clarithromycin of stage II COPD patients with frequent exacerbations Source: Annual Congress 2008 - Management of COPD Year: 2008 Prevalence, features of the course and treatment efficacy airway obstruction in patients with newly diagnosed pulmonary tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings I Year: 2012 Stage IV sarcoidosis: comparison of survival with the general population and causes of death Source: Eur Respir J 2011; 38: 1368-1373 Year: 2011 Effects of pulmonary rehabilitation on peripheral muscle fibre characteristics in COPD patients with gold stages II to IV Source: Annual Congress 2009 - Emerging physiology behind pulmonary rehabilitation Year: 2009 Effects of pulmonary rehabilitation on systemic inflammation in patients with advanced COPD Source: Eur Respir J 2005; 26: Suppl. 49, 721s Year: 2005 The effectiveness of pulmonary rehabilitation in patients diagnosed with interstitial pulmonary fibrosis Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care Year: 2020